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were successfully treated with ganciclovir. 4/19 (21%) have 
relapsed and 6/19 (32%) have died (3 from relapse and 2 from 
TRM and 1 from aGVHD). 2/5 of those who died had a prior 
AHSCT. All deaths occurred within 22.4 months from the trans- 
plant. Those deaths related to TRM occurred within 1.2 months 
and the one death related to GVH occurred at 8.4 months from 
the transplant. The latest relapse occurred ahnost 2 years after the 
transplant. At 5 years the OS is 68% and the PFS is 63%. Our 
data are consistent with other investigators in the field and 
demonstrate hat an allo-HSC'I" appears to be feasible and may 
provide long-term remission in those who don't suffer from the 
early TRM. 
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BAYESIAN SENSITIVITY ANALYSES OF IO0-DAY SURVIVAL WITH 
INTRAVENOUS BUSULFAN VERSUS ALTERNATIVE MYELOABLATIVE 
CONDITIONING THERAPY IN ALLOGENEIC STEM CELL TRANS- 
PLANTATION (ALLO-SCT) FOR CHRONIC MYELOGENOUS 
LEUKEMIA (CML) 
Thall, P.F.; Champ/in, R.E.; A,dersso,, B.S. U.T. M.D. Anclet'son 
Ca1Jcev Cel~tet; Ho'.stoTz, 77(. 
Because the risk of death with allogeneie bone marrow trans- 
plantation (allotx) is ubstantial during the first 100 days, it is 
useful to compare different preparative r gimens in terms of the 
100-day survival probability. Based on data from 1812 CML 
patients who underwent allotx, we evaluated the 100-day mortal- 
ity rates of busulfan-based myeloablative conditioning therapy. 
47 patients received IV busulfan and cyclophosphamide (IV
BuCy2) with allo-SCT at M.D. Anderson Cancer Center 
(MDACC) during the period 1995-1999. The remaining 1765 
patients, whose data were supplied by the International Bone 
Marrow Transplant Registry (IBMTR), received various other 
conditioning regimens, primarily Cy-TBI (-45% of patients) or 
oral BuCy (~35%) in 1990-1998. In the registry no apparent dif- 
ference in early risk could be attributed to different conditioning 
regimens. A problem is that the IV-versus-alternative (treatment) 
effect of primary interest is confounded with a possible (center) 
effect arising from non-treatment differences between the 
MDACC and the IBMTR patients. That is, because the data do 
not  arise from a multi-center randomized trial, the treatment 
effect and center effect are confounded. Additional scientific 
complications are that 1) the IV-MDACC and alternative- 
IBMTR sample sizes are of very different magnitudes, 2) all 47 
IV-MDACC patients urvived 100 days, and 3) three different 
prognostic subgroups were involved (CP-AP-BC). We per- 
forlned Bayesian sensitivity analyses to assess the probability" that 
the IV-alternative treatment effect would favor 1V busulfan, both 
overall and within each prognostic group. The analyses compute 
the probability of a positive IV-versus-alternative tr atment 
effect for each of a range of possible center effect values. Using 
this method, the probability that IV BuCy is superior to the 
alternative treatments ranges from 0.54 to 0.99. A general con 
clusion is that, in terms of I00-day survival, either IV BuCy is 
superior to alternative myeloablative conditioning regimens for 
this indication or, alternatively, allo-SCT CML patients trans- 
planted at MDACC are much more likely to survive at least 100 
days than are patients treated at the other centers contributing to 
these data. 
75 
REPLACEMENT DONOR PROGRAM: THE DUTY TO PROTECT STEM CELL 
DONORS FROM MULTIPLE DONATIONS FOR DIFFERENT PATIENTS 
Gawellek, d.; Rail, G.; Rutt, C.; Baler, D.M. DKMS Deutsche 
Ka~ochemnarksloemte~vlatei, Taebillgen, BadeTz Hz'&v.temberg, Germany. 
Goal of the Replacement Donor Program is to provide an alter- 
native donor for the search centers in case that a donor has com- 
pleted a stem cell donation and is reserved for potential further 
donations for the same patient in a timeframe of actually 2 years. 
First intention is to provide a donor as long as possible for his 
patient afterwards the 2 year suspension. This would enable us to 
provide second or further stem cell donations if required for the 
one patient. Second intention is to protect he donor from 
requests for multiple patients. It could be observed several times 
that post-donation donors are of increased interest for the search 
centers and were requested for confirmatory t ping (CT) multiple 
times. Providing alternative donors would take off the burden 
from a single donor. Third intention is to fill up the gap in HLA- 
phenotypes when a donor is suspended from further donations 
within 2 years post-donation a d to increase the number of high 
resolution typed donors in our donor center. We think that donor 
centers like the DKMS have not only the duty but also the 
responsibility to protect heir donors from excessive demand by 
the search centers. To find a Replacement Donor we perform up 
to 100 DR intermediate r solution or up to 5 DR high resolution 
typings on our own behalf or each donor post donation. Own 
searches and typings are repeated till success as long as a reason- 
able chance remains to find a Replacement Donor. In October 
2002 over 27000 donors will be HLA-DR typed on medium or 
high resolution to provide a Replacement Donor for more then 
1100 donors. Out of these 27000 donors over 600 further equests 
(high resolution typing or confirmato W typing) and 38 donations 
could be observed and not a single stein cell donor donated again 
for another patient. 
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REGIMEN-RELATED TOXICITY (RRT) FOLLOWING REDUCED- 
INTENSITY HEMATOPOIETIC STEM-CELL TRANSPLANTATION 
(RIST): COMPARISON OF BEARMAN'S CRITERIA AND NCI-CTC VER- 
SION 20 
Imataki, 0.; Kami, M.; Saldwmla , M.; Kim, S.; Kojima, R.; Hori, A.; 
Mm:ashig~, 2X(; Makimoto, A.; Tanosaki, R.; Mi,  eishi, S.; Zakaue, Y. 
Hematopoietic Trnnsplantatimz U, it, ]x~atio,al Cmlcel" Create'r, Tokyo 
Ch~w-ku, Tokyo, Jap,m. 
Objective: The primary goal of this study was to evaluate the 
severity of RRT following RIST. The secondary goal was to 
compare value of Bearman's criteria and the National Cancer 
Institute-Common Toxicity Criteria (NCI-CTC) version 2.0 
for predicting the development of RRT after RIST. Methods: 
We reviewed the medical records of 86 patients who under- 
went RIST for the treatment of hematological diseases or solid 
tumors between September 1999 and April 2002. Preparative 
regimens included fludarabine 30 mg/m(2)/day or eladribine 
0.11 mg/m(2)/day on days -8 to -3 and busulfan 4 mg/kg/day 
on days -6 to -5, with or without anti-thymocyteglobulin. RRT 
was graded using two systems, Bearman's criteria and NCI- 
CTC version 2.0, from the day when conditioning regimens 
were initiated until 30 days after transplantation for 8 kinds of 
organ toxicity. Pulmonary toxicity, was re-graded on day 100. 
Comparison of prognostic influences between grade 0-1 RRT 
and grade 2-3 RRT by both Bearman's criteria and NCI-CTC 
was performed with Fisher exact tests. Overall survival of 
patients with each toxicity grade was compared with the 
Kaplan-Meier method and log-rank test. The Cox proportional 
hazards model was used for multivariate analysis. Results: In all 
organs, RRT had a tendency to be graded higher by Bearman's 
criteria and lower by NCI -CTC version 2.0. The highest 
grades, NCI-CTC grade 4 (p=0.003) and Bearman's grade 3 
(p<0.001), were significantly associated with the prognosis. 
Eleven of the 86 (12.8%) patients died of RRT, all of which 
had grade 3 by both Bearman's criteria and NCI-CTC. 4.7% 
(4/86) patients developed Bearman's grade 3 toxicity, two of 
whom died of RRT, whereas NCI-CTC grade 3 to 4 toxicity 
occurred in 50% (43/86) patients, 10 of which died of RRT. In 
a univariate and multivariate analysis of risk of survival, 
although any significant factors were not identified, there is a 
tendency of association with disease status and survival. Con- 
clusion: Since far less RRT was observed after RIST, com- 
pared to data reported after conventional HSCT, Bearman's 
criteria might not be sensitive nough to evaluate the RRT of 
preparative regimens and the ultimate prognosis, compared to 
NCI-CTC. 
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